NCT05339568Recruiting
Patient's Whole Process Follow-up Management(HOPE-1)
A Multicenter, Randomized, Open, Parallel Grouping, Investigator-initiated Study Evaluating the Long-term Benefit of Patients With Locally Advanced/Metastatic Non-small Cell Lung Cancer Followed up Using a Patient-wide Management Platform
Source: ClinicalTrials.gov · Last updated 8 Sept 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1268 (estimated)
- First submitted
- 15 Apr 2022
- Start date
- 22 May 2022
- Primary completion date
- 21 Apr 2030
- Lead sponsor
- Qianfoshan Hospital
- Diseases
- Lung cancer
- NCT number
- NCT05339568
What you commit to
- Study type: Observational
- Planned participants: 1268
- From 22 May 2022 to the primary completion date, 21 Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are expected to undergo radical surgery.
Other illness
- Patients with mental illness.
- Presence of any other malignant tumor.
Other
- Currently participating in clinical trials.
- Subjects who judged by the investigator to be unsuitable to participate in the trial.
Who the study is looking for
- Fully understand the research and voluntarily sign the informed consent form (ICF)
- Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.
- The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).
- According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC.
- Not suitable for radical treatment or refuse surgery.
- The life expectancy is not less than 3 months.
- Be able to use a smartphone.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Shandong First Medical University Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.